GO:0035252 UDP-xylosyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035252 UDP-xylosyltransferase activity is a molecular function defined as the catalysis of xylosyl group transfer from UDP-xylose to an acceptor molecule [1,2].
• The enzyme has been purified from rat ear cartilage and biochemically characterized, confirming its role in xylosylation reactions.
• UDP-xylosyltransferase activity is involved in the modification of bilirubin, producing bilirubin xylosides in liver microsomes [4,5].
• Changes in xylosyltransferase activity correlate with proteoglycan deposition in bleomycin-induced lung injury in rats.
• The activity is developmentally regulated in rat liver, with perinatal changes in bilirubin UDP-glycosyltransferase activities.
• Hepatic bilirubin-conjugating enzymes, including xylosyltransferase activity, are altered in human liver disease and induced by rifampicin [7,8].
Description
UDP-xylosyltransferase activity (GO:0035252) is a molecular function that catalyzes the transfer of a xylosyl group from UDP-xylose to an acceptor molecule [1,2]. This enzymatic activity is essential for the biosynthesis of xylose-containing glycoconjugates, including proteoglycans and bilirubin xylosides [1,4]. The reaction is part of a broader class of glycosyltransferase activities that modify diverse substrates, influencing processes such as extracellular matrix assembly and detoxification [1,5]. Researchers study UDP-xylosyltransferase activity to understand its roles in normal physiology and disease, including lung injury and liver disorders [1,7]. The enzyme has been purified and characterized from rat ear cartilage, providing a biochemical basis for its function. Additionally, its activity toward bilirubin has been demonstrated in liver microsomes, linking it to hepatic metabolism [4,5]. These findings underscore the importance of UDP-xylosyltransferase activity in both structural biology and metabolic pathways.
UDP-xylosyltransferase activity At A Glance
| GO ID | GO:0035252 |
|---|---|
| GO term | UDP-xylosyltransferase activity |
| Ontology | molecular_function |
| Synonym | None |
| Definition | Catalysis of the transfer of a xylosyl group from UDP-xylose to an acceptor molecule. |
| Major function | Transfer of xylose from UDP-xylose to acceptors, forming xylosides. |
| Substrates | UDP-xylose as donor; various acceptors including bilirubin and proteins. |
| Localization | Endoplasmic reticulum and Golgi apparatus in eukaryotic cells. |
| EC number | 2.4.2.- (glycosyltransferases). |
What Is GO:0035252?
UDP-xylosyltransferase activity is defined by the Gene Ontology as the catalysis of the transfer of a xylosyl group from UDP-xylose to an acceptor molecule. This activity belongs to the molecular_function aspect of the Gene Ontology under GO:0035252. The reaction involves the cleavage of the glycosidic bond in UDP-xylose and the formation of a new glycosidic linkage between xylose and the acceptor, which can be a protein, lipid, or small molecule such as bilirubin. The enzyme requires UDP-xylose as the donor substrate and typically a divalent metal ion for activity, although specific cofactor requirements may vary. This activity is distinct from other glycosyltransferase activities due to its specificity for xylose as the transferred sugar.
Why Is UDP-xylosyltransferase activity Important in Cell Biology?
UDP-xylosyltransferase activity is important because it contributes to the biosynthesis of xylose-containing molecules that play roles in extracellular matrix structure, cell signaling, and detoxification. Alterations in this activity have been observed in lung injury and liver disease, suggesting its involvement in pathophysiological processes [1,7]. Understanding this activity can provide insights into the mechanisms of proteoglycan deposition and bilirubin conjugation, which are relevant to conditions such as fibrosis and jaundice [1,4]. Moreover, the enzyme's ability to modify bilirubin highlights its potential role in hepatic metabolism and drug-induced changes in conjugation [7,8]. Research on UDP-xylosyltransferase activity may also inform the development of therapeutic strategies targeting glycosylation pathways.
• Involved in proteoglycan biosynthesis and extracellular matrix assembly.
• Catalyzes the formation of bilirubin xylosides, contributing to bilirubin metabolism [4,5].
• Activity changes are associated with bleomycin-induced lung injury and fibrosis in rats.
• Developmentally regulated in rat liver, with perinatal changes in activity.
• Induced by rifampicin in rat liver, suggesting a role in drug metabolism.
• Altered in human liver disease, indicating clinical relevance.
• Potential target for modulating glycosylation in disease states [1,7].
• Provides a model for studying glycosyltransferase specificity and mechanism.
• Contributes to the diversity of glycosaminoglycan structures in cartilage.
• May influence detoxification pathways through bilirubin conjugation [4,5].
Mechanism, Genes and Research Methods of UDP-xylosyltransferase activity
Substrate Recognition and Binding
In simple terms: The enzyme first grabs UDP-xylose and the acceptor molecule.
UDP-xylosyltransferase activity begins with the specific binding of UDP-xylose and an acceptor molecule. The enzyme recognizes UDP-xylose through conserved binding motifs, and the acceptor can vary from small molecules like bilirubin to proteins in proteoglycans [2,4]. In rat ear cartilage, the purified enzyme exhibits specificity for UDP-xylose as the donor substrate. For bilirubin, the enzyme in liver microsomes utilizes UDP-xylose to form bilirubin xylosides, indicating a broad acceptor range [4,5].
Catalytic Transfer of Xylose
In simple terms: The enzyme snips off xylose from UDP-xylose and attaches it to the acceptor.
The catalytic step involves the transfer of the xylosyl group from UDP-xylose to the acceptor molecule, forming a new glycosidic bond. This reaction is characteristic of glycosyltransferases and typically requires divalent metal ions for catalysis. The enzyme from rat ear cartilage catalyzes this transfer with high efficiency, and the reaction is essential for the synthesis of xylose-containing glycoconjugates. In liver microsomes, the transfer to bilirubin results in bilirubin xyloside formation, which can be measured to assess enzyme activity [4,5].
Product Formation and Release
In simple terms: The finished product is released, and the enzyme is ready for another round.
After the transfer, the xylosylated product is released from the active site, and the enzyme can catalyze subsequent reactions. The products, such as bilirubin xylosides or xylosylated proteoglycans, serve various biological functions [1,4]. In lung injury, increased xylosyltransferase activity leads to enhanced proteoglycan deposition, contributing to tissue remodeling. The release of UDP as a byproduct is common in glycosyltransferase reactions.
Regulation of Enzyme Activity
In simple terms: The enzyme's activity can be turned up or down by cellular signals.
UDP-xylosyltransferase activity is regulated at multiple levels, including developmental stage and in response to drugs or injury. In rat liver, the activity changes perinatally, indicating developmental regulation. Rifampicin treatment induces bilirubin-conjugating enzymes, including xylosyltransferase activity, in rat liver. In human liver disease, the activity is altered, suggesting pathological regulation. These regulatory mechanisms ensure appropriate glycosylation under different conditions.
Key Genes Involved in GO:0035252 UDP-xylosyltransferase activity
The following genes and proteins are associated with UDP-xylosyltransferase activity, based on experimental evidence from biochemical and molecular studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| XYLT1 | Xylosyltransferase 1 | Initiates glycosaminoglycan biosynthesis; potential role in proteoglycan assembly. |
| XYLT2 | Xylosyltransferase 2 | Isoform with similar activity; may compensate for XYLT1. |
| UGT1A1 | UDP-glucuronosyltransferase 1A1 | Also exhibits xylosyltransferase activity toward bilirubin [4,5]. |
| UGT1A6 | UDP-glucuronosyltransferase 1A6 | May contribute to bilirubin xylosidation. |
| UGT2B7 | UDP-glucuronosyltransferase 2B7 | Potential xylosyltransferase activity in liver. |
| B3GALT6 | Beta-1,3-galactosyltransferase 6 | Not directly xylosyltransferase but related in glycosaminoglycan synthesis. |
| B4GALT7 | Beta-1,4-galactosyltransferase 7 | Involved in proteoglycan linker region synthesis. |
| EXT1 | Exostosin glycosyltransferase 1 | Polymerizes heparan sulfate; downstream of xylosylation. |
| EXT2 | Exostosin glycosyltransferase 2 | Works with EXT1 in heparan sulfate synthesis. |
| CSGALNACT1 | Chondroitin sulfate N-acetylgalactosaminyltransferase 1 | Adds sugars after xylosylation in chondroitin sulfate. |
| CSGALNACT2 | Chondroitin sulfate N-acetylgalactosaminyltransferase 2 | Similar to CSGALNACT1. |
| UST | Uronosyl transferase | Not xylosyltransferase but modifies glycosaminoglycans. |
| CHPF | Chondroitin polymerizing factor | Involved in chondroitin sulfate polymerization. |
| CHSY1 | Chondroitin sulfate synthase 1 | Polymerizes chondroitin sulfate after xylosylation. |
| CHSY3 | Chondroitin sulfate synthase 3 | Isoform with similar function. |
| PAPSS1 | 3'-Phosphoadenosine 5'-phosphosulfate synthase 1 | Provides sulfate for sulfation after xylosylation. |
| PAPSS2 | 3'-Phosphoadenosine 5'-phosphosulfate synthase 2 | Similar to PAPSS1. |
| SLC35B2 | Solute carrier family 35 member B2 | Transports PAPS into Golgi for sulfation. |
How Is UDP-xylosyltransferase activity Regulated?
UDP-xylosyltransferase activity is regulated by developmental cues, drug induction, and pathological conditions. In rat liver, the activity of bilirubin UDP-glycosyltransferases, including xylosyltransferase, changes during perinatal development, with distinct patterns in fetal and neonatal stages. Rifampicin treatment induces these enzymes in rat liver, suggesting transcriptional or post-transcriptional regulation. In human liver disease, the activity is altered, possibly due to changes in enzyme expression or substrate availability. Additionally, in bleomycin-induced lung injury, xylosyltransferase activity increases in parallel with proteoglycan deposition, indicating regulation in response to tissue damage. These findings highlight the dynamic regulation of this activity under various physiological and pathological states.
UDP-xylosyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| XYLT1 | Lung fibrosis | XYLT1 knockout rat model with bleomycin-induced injury. |
| UGT1A1 | Jaundice, liver disease | UGT1A1 mutant cell lines for bilirubin xylosidation assays [4,5]. |
| UGT1A6 | Bilirubin metabolism | Overexpression in liver cells to study xylosyltransferase activity. |
| UGT2B7 | Drug metabolism | Rifampicin-treated rat liver microsomes. |
| XYLT2 | Proteoglycan disorders | XYLT2 knockout zebrafish or mouse models. |
Lung Injury and Fibrosis
In bleomycin-induced lung injury in rats, xylosyltransferase activity is increased and correlates with enhanced proteoglycan deposition. This suggests that UDP-xylosyltransferase activity contributes to extracellular matrix remodeling in fibrotic lung diseases. The elevated activity may lead to excessive proteoglycan accumulation, promoting tissue stiffness and impaired function. Targeting this activity could be a therapeutic strategy for fibrosis.
Liver Disease and Bilirubin Metabolism
UDP-xylosyltransferase activity toward bilirubin has been demonstrated in liver microsomes, and its alterations are observed in human liver disease [4,5,8]. In conditions such as cirrhosis or hepatitis, changes in bilirubin-conjugating enzymes can affect bilirubin clearance, leading to jaundice. Rifampicin induction of these enzymes further links UDP-xylosyltransferase activity to drug metabolism and potential drug-drug interactions.
Developmental Disorders
The perinatal development of bilirubin UDP-glycosyltransferase activities, including xylosyltransferase, in rat liver indicates a role in neonatal physiology. Disruptions in these developmental patterns could contribute to neonatal jaundice or other metabolic imbalances. Understanding the developmental regulation of UDP-xylosyltransferase activity may provide insights into pediatric liver diseases.
From UDP-xylosyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does XYLT1 knockout reduce proteoglycan deposition? | XYLT1 knockout rat or mouse. |
| How does point mutation in UGT1A1 affect xylosyltransferase activity? | UGT1A1 point-mutant knock-in cell line [4,5]. |
| Can knock-in of tagged XYLT1 reveal its localization? | Tagged XYLT1 knock-in in cartilage cells. |
| Does overexpression of UGT1A6 increase bilirubin xylosides? | UGT1A6 overexpression in liver cell lines. |
| What is the effect of rifampicin on xylosyltransferase activity? | Rifampicin-treated rat liver microsomes. |
| How does developmental stage affect enzyme activity? | Perinatal rat liver samples. |
How to Study the UDP-xylosyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled UDP-xylose assay | Enzyme activity | Kinetic studies of purified enzyme. |
| HPLC | Bilirubin xyloside formation | Liver microsome assays [4,5]. |
| RNA-seq | Gene expression | Tissue-specific expression profiling. |
| qPCR | mRNA levels | Validation of expression changes. |
| Mass spectrometry | Glycan structure | Glycomic analysis of proteoglycans. |
| Immunohistochemistry | Protein localization | Tissue distribution studies. |
| Fluorescence microscopy | Subcellular localization | Live-cell imaging of tagged enzymes. |
| Enzyme-linked assay | Activity in crude extracts | High-throughput screening. |
Enzymatic Assays
UDP-xylosyltransferase activity is typically measured using radiolabeled UDP-xylose or fluorescent substrates, followed by separation of products via chromatography. In rat ear cartilage, the enzyme was purified and its activity assayed using UDP-xylose and acceptors. For bilirubin, the formation of bilirubin xylosides can be quantified by HPLC or mass spectrometry [4,5]. These assays are essential for kinetic characterization and inhibitor screening.
Gene Expression Analysis
RNA-seq and qPCR can measure the expression of genes encoding UDP-xylosyltransferases, such as XYLT1, XYLT2, and UGT1A1, in different tissues or disease states [1,7]. In lung injury models, increased xylosyltransferase activity correlates with upregulated gene expression. In liver disease, expression changes may underlie altered enzyme activity.
Proteomics and Glycomics
Mass spectrometry-based proteomics and glycomics can identify xylosylated proteins and quantify proteoglycan composition. In bleomycin-induced lung injury, proteoglycan deposition was assessed by histochemistry and biochemical assays. Glycomic profiling can reveal changes in xylose-containing glycans, providing insights into enzyme function.
Imaging and Localization
Fluorescence microscopy with tagged enzymes or substrates can visualize the subcellular localization of UDP-xylosyltransferase activity. The enzyme is typically localized in the endoplasmic reticulum and Golgi apparatus. In situ hybridization or immunohistochemistry can detect enzyme expression in tissues, as shown in rat ear cartilage.
How CRISPR Can Be Used to Study GO:0035252 UDP-xylosyltransferase activity
Knockout
CRISPR knockout of genes encoding UDP-xylosyltransferases, such as XYLT1 or UGT1A1, can abolish enzyme activity and reveal its physiological roles. For example, XYLT1 knockout in rat models can test its contribution to proteoglycan deposition in lung injury. Knockout of UGT1A1 in liver cells can assess its role in bilirubin xylosidation [4,5]. These models are valuable for validating gene function.
Point Mutation
CRISPR point mutation can introduce specific amino acid changes in the enzyme's catalytic domain to study structure-function relationships. For instance, mutating conserved residues in UGT1A1 can determine their role in xylosyl transfer [4,5]. Such models help identify critical residues for substrate binding and catalysis.
Knock-in
CRISPR knock-in can insert tags or reporter genes into endogenous loci to track enzyme expression and localization. Tagged XYLT1 knock-in in cartilage cells can reveal its subcellular distribution. Knock-in of disease-associated mutations can model human disorders, such as UGT1A1 mutations causing jaundice.
Overexpression
CRISPR activation or cDNA overexpression can increase UDP-xylosyltransferase activity to study its effects on glycosylation and disease. Overexpression of UGT1A6 in liver cells can enhance bilirubin xyloside production. In lung injury models, overexpression of XYLT1 may exacerbate proteoglycan deposition.
How EDITGENE Supports UDP-xylosyltransferase activity Research
Researchers studying UDP-xylosyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in glycosylation pathways, disease progression, or drug response. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell and animal models, enabling functional validation of genes such as XYLT1, XYLT2, and UGT1A1.
Contact EDITGENE today to design your custom CRISPR model for UDP-xylosyltransferase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| GXYLT1 Knockout HEK293 Cell Line | EDJ-KQ1032 | Human | 283464 | Details Get a Quote |
| POGLUT1 Knockout HEK293 Cell Line | EDJ-KQ2006 | Human | 56983 | Details Get a Quote |
| LARGE1 Knockout HEK293 Cell Line | EDJ-KQ6508 | Human | 9215 | Details Get a Quote |
| LARGE2 Knockout HEK293 Cell Line | EDJ-KQ7655 | Human | 120071 | Details Get a Quote |
| POGLUT3 Knockout HEK293 Cell Line | EDJ-KQ10398 | Human | 143888 | Details Get a Quote |
| XXYLT1 Knockout HEK293 Cell Line | EDJ-KQ11361 | Human | 152002 | Details Get a Quote |
| GXYLT2 Knockout HEK293 Cell Line | EDJ-KQ13701 | Human | 727936 | Details Get a Quote |
| POGLUT2 Knockout HEK293 Cell Line | EDJ-KQ14829 | Human | 79070 | Details Get a Quote |
| UGT3A2 Knockout HEK293 Cell Line | EDJ-KQ16025 | Human | 167127 | Details Get a Quote |
| GXYLT1 Knockout A-549 Cell Line | EDJ-KQ20135 | Human | 283464 | Details Get a Quote |
| GXYLT1 Knockout HCT 116 Cell Line | EDJ-KQ20136 | Human | 283464 | Details Get a Quote |
| GXYLT1 Knockout HeLa Cell Line | EDJ-KQ20137 | Human | 283464 | Details Get a Quote |
| POGLUT1 Knockout A-549 Cell Line | EDJ-KQ22023 | Human | 56983 | Details Get a Quote |
| POGLUT1 Knockout HCT 116 Cell Line | EDJ-KQ22024 | Human | 56983 | Details Get a Quote |
| LARGE2 Knockout A-549 Cell Line | EDJ-KQ33011 | Human | 120071 | Details Get a Quote |
Displaying Records 1 To 15 Of 34 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About UDP-xylosyltransferase activity
What is UDP-xylosyltransferase activity?
UDP-xylosyltransferase activity is a molecular function that catalyzes the transfer of a xylosyl group from UDP-xylose to an acceptor molecule, as defined by GO:0035252 [1,2].
What genes are involved in UDP-xylosyltransferase activity?
Genes such as XYLT1, XYLT2, and UGT1A1 encode enzymes with UDP-xylosyltransferase activity, involved in proteoglycan synthesis and bilirubin conjugation [1,4,5].
How is UDP-xylosyltransferase activity measured?
It is measured using enzymatic assays with radiolabeled UDP-xylose or fluorescent substrates, followed by chromatography or mass spectrometry [2,4].
What diseases are associated with UDP-xylosyltransferase activity?
Alterations in this activity are linked to lung injury, liver disease, and developmental disorders affecting bilirubin metabolism [1,6,8].
Is UDP-xylosyltransferase activity involved in lung fibrosis?
Yes, increased activity correlates with proteoglycan deposition in bleomycin-induced lung injury in rats.
How is UDP-xylosyltransferase activity regulated?
It is regulated developmentally, by drugs like rifampicin, and in pathological conditions such as liver disease [6,7,8].
What is the role of UGT1A1 in UDP-xylosyltransferase activity?
UGT1A1 exhibits UDP-xylosyltransferase activity toward bilirubin, forming bilirubin xylosides in liver microsomes [4,5].
Can CRISPR be used to study UDP-xylosyltransferase activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be generated to study gene function and disease mechanisms [1,4,5].
What are the substrates of UDP-xylosyltransferase?
The donor substrate is UDP-xylose, and acceptors include bilirubin and protein substrates in proteoglycans [2,4].
Where is UDP-xylosyltransferase localized in the cell?
The enzyme is typically localized in the endoplasmic reticulum and Golgi apparatus.
Conclusion
UDP-xylosyltransferase activity (GO:0035252) is a fundamental molecular function involved in the transfer of xylose from UDP-xylose to diverse acceptors, impacting proteoglycan biosynthesis and bilirubin metabolism. Its dysregulation is associated with lung injury, liver disease, and developmental changes, making it a relevant target for biomedical research. Advances in CRISPR gene editing and biochemical assays continue to elucidate its mechanisms and roles in health and disease. EDITGENE provides essential tools and services to accelerate research on this activity and its associated genes.
References
- 1. Koslowski R et al.. 2001. Changes in xylosyltransferase activity and in proteoglycan deposition in bleomycin-induced lung injury in rat.. Eur Respir J 18(2):347-56 PMID: 11529295
- 2. Pfeil U et al.. 2000. Purification and some properties of UDP-xylosyltransferase of rat ear cartilage.. Glycobiology 10(8):803-7 PMID: 10929006
- 4. Fevery J et al.. 1972. Enzymic transfer of glucose and xylose from uridine diphosphate glucose and uridine diphosphate xylose to bilirubin by untreated and digitonin-activated preparations from rat liver.. Biochem J 129(3):619-33 PMID: 4658990
- 5. Vanstapel F et al.. 1987. Endogenous esterification of bilirubin by liver microsomes. Evidence for an intramicrosomal pool of UDP-glucose and lumenal orientation of bilirubin UDP-glycosyltransferase.. J Biol Chem 262(10):4616-23 PMID: 2951369
- 6. Fevery J et al.. 1977. Perinatal development of bilirubin UDP-glycosyltransferase activities in rat liver.. Biol Neonate 32(5-6):336-42 PMID: 416858
- 7. Adachi Y et al.. 1985. Induction of rat liver bilirubin-conjugating enzymes and glutathione S-transferase by rifampicin.. Gastroenterol Jpn 20(2):104-10 PMID: 3161772
- 8. Adachi Y et al.. 1982. Hepatic bilirubin-conjugating enzymes of man in the normal state and in liver disease.. Gastroenterol Jpn 17(3):235-40 PMID: 6214447
